Emily Chan
Amgen (United States)(US)King's College London(GB)Tuen Mun Hospital(CN)Helmholtz Zentrum München(DE)Electronic Sensor Technology (United States)(US)Stanford Medicine(US)Technical University of Munich(DE)Stanford University(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Pancreatic and Hepatic Oncology Research, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research
Most-Cited Works
- → Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors(2012)1,105 cited
- → Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer(2010)997 cited
- → Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial(2015)418 cited
- → Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer(2013)220 cited
- → Rectal Cancer, Version 2.2015(2015)214 cited
- → Metastatic Colon Cancer, Version 3.2013(2013)162 cited